Anti-CD3 & EpCAM Antibody (Catumaxomab-like (huIgG1-rat IgG2b))

Catumaxomab is a trifunctional bispecific IgG2 antibody composed of the IgG2a chain of a mouse anti-EpCAM antibody and the IgG2b chain of a rat anti-CD3 antibody. Its targets are epithelial cell adhesion molecule (EpCAM) and the T-cell surface antigen CD3. By simultaneously binding to EpCAM (a target highly expressed in epithelial-derived tumors) on tumor cells and CD3 on T cells, and via its Fc fragment binding to Fcγ receptors on the surface of accessory cells such as macrophages and natural killer (NK) cells, the antibody forms a tri-cellular complex among tumor cells, T cells, and accessory cells. This complex synergistically activates multiple immune effects including T cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), ultimately achieving effective elimination of EpCAM-positive tumor cells. Its primary clinical application is intraperitoneal perfusion for the treatment of malignant ascites caused by EpCAM-positive epithelial-derived tumors. This product is a research-grade preparation in the form of Catumaxomab (huIgG1-rat IgG2b), consisting of the IgG1 chain of a human anti-EpCAM antibody and the IgG2b chain of a rat anti-CD3 antibody.